Evidence map›Paper›PMID 38292868›Full record

ArticleFrontiers in immunology2024

Single-cell disulfidptosis regulator patterns guide intercellular communication of tumor microenvironment that contribute to kidney renal clear cell carcinoma progression and immunotherapy.

Kangjie Xu, Dongling Li, Jinke Qian, Yanhua Zhang, Minglei Zhang, Hai Zhou, Xuefeng Hou, Jian Jiang, Zihang Zhang, Hang Sun and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Progenitor CD8Apoptosis : an international journal on programmed cell death · 2026
    Article
  5. Review
  6. Disulfidptosis in tumor progression.Cell death discovery · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kangjie Xu *Central Laboratory Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Dongling Li *Nephrology Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Jinke QianUrology Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Yanhua ZhangObstetrics and Gynecology Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Minglei ZhangOncology Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Hai ZhouCentral Laboratory Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Xuefeng HouCentral Laboratory Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Jian JiangCentral Laboratory Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Zihang ZhangPathology Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Hang SunUrology Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Guodong ShiMedical Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Hua DaiYangzhou University Clinical Medical College, Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Yancheng, Jiangsu, China.
Hui LiuUrology Department, Binhai County People's Hospital, Yancheng, Jiangsu, China.
Binzhou People's Hospital · CNYangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Disulfidptosis, an emerging type of programmed cell death, plays a pivotal role in various cancer types, notably impacting the progression of kidney renal clear cell carcinoma (KIRC) through the tumor microenvironment (TME). However, the specific involvement of disulfidptosis within the TME remains elusive. Methods: Analyzing 41,784 single cells obtained from seven samples of KIRC through single-cell RNA sequencing (scRNA-seq), this study employed nonnegative matrix factorization (NMF) to assess 24 disulfidptosis regulators. Pseudotime analysis, intercellular communication mapping, determination of transcription factor activities (TFs), and metabolic profiling of the TME subgroup in KIRC were conducted using Monocle, CellChat, SCENIC, and scMetabolism. Additionally, public cohorts were utilized to predict prognosis and immune responses within the TME subgroup of KIRC. Results: Through NMF clustering and differential expression marker genes, fibroblasts, macrophages, monocytes, T cells, and B cells were categorized into four to six distinct subgroups. Furthermore, this investigation revealed the correlation between disulfidptosis regulatory factors and the biological traits, as well as the pseudotime trajectories of TME subgroups. Notably, disulfidptosis-mediated TME subgroups (DSTN+CD4T-C1 and FLNA+CD4T-C2) demonstrated significant prognostic value and immune responses in patients with KIRC. Multiple immunohistochemistry (mIHC) assays identified marker expression within both cell clusters. Moreover, CellChat analysis unveiled diverse and extensive interactions between disulfidptosis-mediated TME subgroups and tumor epithelial cells, highlighting the TNFSF12-TNFRSF12A ligand-receptor pair as mediators between DSTN+CD4T-C1, FLNA+CD4T-C2, and epithelial cells. Conclusion: Our study sheds light on the role of disulfidptosis-mediated intercellular communication in regulating the biological characteristics of the TME. These findings offer valuable insights for patients with KIRC, potentially guiding personalized immunotherapy approaches.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCell CommunicationHumansImmunotherapyKidneyTumor Microenvironmentdisulfidptosisimmunotherapykidney renal clear cell carcinomamultiple immunohistochemistryprognosissingle-celltumor microenvironment

Identifiers

PMID38292868
PMCPMC10824999
OpenAlexW4390917258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.